Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys.

Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jan 2001Cited by 185 (Europe PMC)

PMID11149480DOI10.1359/jbmr.2001.16.1.157PepBankPUB-11149480

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, PTH increased intracortical porosity in a dose-dependent manner.
In plain wordsIn monkeys, PTH increased cortical bone porosity as dose increased.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseIntracortical porosity
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg daily · subcutaneous · 18 monthsAs given in this study (cynomolgus monkey).
Source sentences
Summary
PTH dose dependently increased intracortical porosity.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948001
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, increased porosity during PTH treatment had no significant detrimental effect on bone mechanical properties.
In plain wordsIn monkeys, increased porosity during PTH treatment did not significantly impair bone mechanical properties.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone mechanical properties
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg daily · subcutaneous · 18 monthsAs given in this study (cynomolgus monkey).
Source sentences
Summary
However, the increased porosity did not have a significant detrimental effect on the mechanical properties of the bone.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948002
03AnimalAnimal study (in vivo)Other
In PTH-treated ovariectomized monkeys, most porosity was near the endocortical surface, where its mechanical effect was small.
In plain wordsIn monkeys treated with PTH, most porosity was near the inner cortical surface, where its mechanical effect was small.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePorosity distribution
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 18 monthsAs given in this study (cynomolgus monkey).
Source sentences
Summary
Most porosity was concentrated near the endocortical surface where its mechanical effect is small.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948003
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys receiving the higher PTH dose, cortical area increased.
In plain wordsIn monkeys, the higher PTH dose increased cortical bone area.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical area
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5.0 microg/kg daily · subcutaneous · 18 monthsAs given in this study (cynomolgus monkey).
Source sentences
Summary
In PTH5 monkeys, cortical area (Ct.Ar) and cortical thickness (Ct.Th) increased because of a significantly increased endocortical mineralizing surface.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948004
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys receiving the higher PTH dose, cortical thickness increased.
In plain wordsIn monkeys, the higher PTH dose increased cortical bone thickness.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical thickness
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5.0 microg/kg daily · subcutaneous · 18 monthsAs given in this study (cynomolgus monkey).
Source sentences
Summary
In PTH5 monkeys, cortical area (Ct.Ar) and cortical thickness (Ct.Th) increased because of a significantly increased endocortical mineralizing surface.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948005
06AnimalAnimal study (in vivo)Mechanism
In ovariectomized monkeys receiving the higher PTH dose, endocortical mineralizing surface increased significantly.
In plain wordsIn monkeys, the higher PTH dose increased the mineralizing surface inside cortical bone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical mineralizing surface
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5.0 microg/kg daily · subcutaneous · 18 monthsAs given in this study (cynomolgus monkey).
Source sentences
Summary
In PTH5 monkeys, cortical area (Ct.Ar) and cortical thickness (Ct.Th) increased because of a significantly increased endocortical mineralizing surface.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948006
07AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, porosity after lower-dose PTH withdrawal declined to sham values.
In plain wordsIn monkeys, porosity after lower-dose PTH withdrawal decreased to sham values.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePorosity after low-dose withdrawal
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Comparator
Sham
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 microg/kg daily · subcutaneous · 12 months followed by 6 months withdrawalAs given in this study (cynomolgus monkey).
Source sentences
Summary
After withdrawal of treatment, porosity in PTH1-W animals declined to sham values, but porosity in PTH5-W animals remained significantly elevated compared with OVX and sham.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948007
08AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, porosity remained elevated versus ovariectomized controls after higher-dose PTH withdrawal.
In plain wordsIn monkeys, porosity remained higher than ovariectomized controls after higher-dose PTH withdrawal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePorosity after high-dose withdrawal versus ovariectomized controls
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Comparator
Ovariectomized vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5.0 microg/kg daily · subcutaneous · 12 months followed by 6 months withdrawalAs given in this study (cynomolgus monkey).
Source sentences
Summary
After withdrawal of treatment, porosity in PTH1-W animals declined to sham values, but porosity in PTH5-W animals remained significantly elevated compared with OVX and sham.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948008
09AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, porosity remained elevated versus sham after higher-dose PTH withdrawal.
In plain wordsIn monkeys, porosity remained higher than sham after higher-dose PTH withdrawal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePorosity after high-dose withdrawal versus sham
Study
cynomolgus monkeyn: not reported in source
Ovariectomized female cynomolgus monkeys
Comparator
Sham
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5.0 microg/kg daily · subcutaneous · 12 months followed by 6 months withdrawalAs given in this study (cynomolgus monkey).
Source sentences
Summary
After withdrawal of treatment, porosity in PTH1-W animals declined to sham values, but porosity in PTH5-W animals remained significantly elevated compared with OVX and sham.
3 context sentences(design, population, supporting numbers)
Summary · context
OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1-34) LY333334 at 1.0 microg/kg (PTH1), 5.0 microg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX).
Summary · context
After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle.
Summary · context
After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis.
Report a problemFND-1114948009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.